BTC Health (ASX: BTC) is an ASX-listed Pooled Development Fund* which makes active investments in businesses that acquire, develop and distribute medical products in Australia and New Zealand.
The company is building a group of high-growth businesses which together are focused on providing access to innovative medical products and specialised pharmaceuticals from around the world.
Responsible for the commercialisation and distribution of medical devices and medical consumables in acute pain management and neuro-spinal surgery. The company is registered with the TGA and manages all supply chain logistics, quality compliance, pricing, sales, marketing and customer interactions.
In-licenses and acquires specialist pharmaceuticals from around the world, and undertakes the registration, development, sales and marketing of specialised medicines that serve niche markets and rare diseases. BTC Pharma builds long-term partnerships with international companies that do not have a direct presence in Australia and New Zealand.
A wholly owned company of BTC Health, dedicated to the marketing and distribution of highly specialised cardiovascular medical equipment and single-use consumable products, used by cardiac surgeons and critical care perfusionists.
Executive Chairman
Dr Treagus is a physician and entrepreneur with over 20 years’ experience in all aspects of the international pharmaceutical and biotechnology industry. Richard served as Chief Executive of ASX-listed company Acrux (ASX Code: ACR) until 2012 and was formerly the Executive Chairman of Neuren Pharmaceuticals Limited (ASX Code: NEU). Richard is also part of our Leadership Team.
Non-Executive Director
Martin has over 20 years’ specialised financial experience in the pharmaceutical and medical industry. He joined Litha Healthcare Holdings in 1996 as Group Financial Director, until his appointment as Chief Financial Officer of the JSE-listed Litha Healthcare Group Limited in May 2010. During his tenure at Litha Healthcare Holdings, Martin was instrumental in growing the company from a R40 million to a R1 billion-a-year organisation, and continued this growth trajectory with Litha Healthcare Group Ltd. Martin was nominated as a finalist for the Ernst & Young World Entrepreneur Award.
Non-Executive Director
Ms McNeill has extensive experience in the finance and health sectors, including 20 years working in the Federal government departments of finance, industry and health. Felicity is a private consultant with specialist expertise spanning strategic policy and regulatory reforms within the health sector. She is the co-founder and current Chair of Better Access Australia, and has previously held the roles of President of Hepatitis Australia and CEO of the Organ and Tissue Authority.
Non-Executive Director
Dr Kadish is an experienced healthcare executive and ASX-listed company director with more than 30 years of experience across South Africa, the United States and Australia. He most recently served as Managing Director and Chief Executive Officer of Integral Diagnostics Limited (ASX: IDX), which he led from 2017 as it grew into the second largest radiology provider in Australia, with a significant presence in New Zealand. He also serves as a non-executive director of Teaminvest Private Group Limited (ASX: TIP) and was a director of the Australian Diagnostic Imaging Association (ADIA) for several years. Since relocating to Australia in 2006, he has been CEO and Managing Director of Healthcare Australia and of Pulse Health Group Limited (ASX: PHG), CEO of Laverty Pathology and Chief Operating Officer of Greencross Limited (ASX: GXL).
Chief Financial Officer and Company Secretary
Salesh, with more than 20 years’ experience in the high-growth healthcare sector, joined BTC Health in March 2025. He brings over 18 years of financial leadership experience from Universal Biosensors, Inc., a Delaware, US company listed on the ASX. Before that he was Chief Financial Officer and Company Secretary of Pearl Healthcare Limited, an ASX-listed entity in the manufacturing and healthcare sector, and spent 13 years in the Business Services, Audit and Financial Advisory Services divisions of KPMG, in both the Melbourne and Fiji offices.
Chief Operations Officer
Josh joined BTC Health in 2023, with over 9 years of experience across diverse industries. Before joining BTC Health, Josh was CFO of Kingfisher Medical in South Africa.
Quality and Regulatory
Jeanette is a highly experienced professional with approximately 30 years’ experience in the healthcare industry. She has held roles in production, regulatory affairs and quality assurance.
Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor’s assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.